BCL-2 inhibition: stemming the tide of myeloid malignancies
- PMID: 23472867
- PMCID: PMC3705714
- DOI: 10.1016/j.stem.2013.02.006
BCL-2 inhibition: stemming the tide of myeloid malignancies
Abstract
Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. As reported in this issue of Cell Stem Cell, Lagadinou et al. (2013) and Goff et al. (2013) support selective targeting of LSCs by small molecule antagonists of anti-apoptotic BCL-2 family proteins.
Copyright © 2013 Elsevier Inc. All rights reserved.
Comment on
-
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.Cell Stem Cell. 2013 Mar 7;12(3):329-41. doi: 10.1016/j.stem.2012.12.013. Epub 2013 Jan 17. Cell Stem Cell. 2013. PMID: 23333149 Free PMC article.
-
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.Cell Stem Cell. 2013 Mar 7;12(3):316-28. doi: 10.1016/j.stem.2012.12.011. Epub 2013 Jan 17. Cell Stem Cell. 2013. PMID: 23333150 Free PMC article.
References
-
- Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375–388. - PubMed
-
- Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Coretes J, Minden M, Paterson B, Caligiuri M, Dick J. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:345–648. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
